![UMN logo](/assets/logo-14ca9c5bc764343ea0b1ec3edef3d39b15c438f8eb603b1a5fbf826128a74246.png)
StudyFinder
MT2016-11 :Autologous Stem Cell Transplant In Patients with Hodgkin Lymphoma (HL) and Non-Hodgkin Lymphomas (NHL)
![](/assets/flag-998f631fa7bef54098575ae881e66e71315bfae4a5d1ffb34ab8f527fcff0600.jpg)
Recruiting
The primary objective is to estimate overall survival (OS) at 3 years post-transplant for patients who received the radiation free preparative regimen BEAM.
Not specified
Inclusion Criteria:
• up to 75 years of age
• diagnosis of Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Mature B cell Lymphoma, or Mature T cell Lymphoma
• at least 4 weeks from previous chemotherapy; 6 weeks from nitrosoureas
• women of child bearing potential and sexually active males with partners of child bearing potential must agree to use adequate birth control for the duration of treatment
• see link to clinicaltrials.gov for complete criteria
Exclusion Criteria:
• women who are pregnant or breastfeeding
• chemotherapy resistant disease
• unrelated active infection
Drug: AraC, Drug: BCNU, Drug: Cyclophosphamide, Drug: Etoposide, Biological: G-CSF, Drug: Melphalan, Procedure: Peripheral blood stem cell transplantation, Radiation: Total Body Irradiation
Cancer
Clinics and Surgery Center (CSC), Hodgkin Lymphoma, Non-Hodgkin Lymphoma
Veronika Bachanova - bach0173@umn.edu
Veronika Bachanova, MD
PHASE2
1611M99805
19183
See this study on ClinicalTrials.gov